In this video, health-care analyst David Williamson walks investors through today's Aveo Pharmaceuticals bloodbath. Shares are down 50% as an FDA advisory committee voted overwhelmingly against its drug candidate tivozanib. Find out why the decision shook out like it did, and if Aveo is a bad news buy after today's extreme plunge.
What macro trend was Warren Buffett referring to when he said, "This is the tapeworm that's eating at American competitiveness?" Find out in our free report, What's Really Eating At America's Competitiveness. You'll also discover an idea to profit as companies work to eradicate this efficiency-sucking tapeworm. Just click here for free, immediate access.
The article An FDA Advisory Committee Kill Shot originally appeared on Fool.com.
David Williamson owns shares of Pfizer. Follow David on Twitter: @MotleyDavid.The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.